James Hollingshead serves as the President and Chief Executive Officer at Insulet Corporation, a leading medical device company focused on developing innovative insulin delivery systems for people with diabetes. Prior to joining Insulet, Hollingshead held several high-level positions in the healthcare industry, showcasing his extensive experience and leadership skills. He previously served as the President of the Global Vision Care business at Johnson & Johnson, where he led the strategic direction and growth of the company's eye health portfolio. Before that, he spent nearly two decades at Abbott Laboratories in various roles, including Vice President of Global Diabetes Care, where he played a key role in developing and launching groundbreaking diabetes management solutions. At Insulet, Hollingshead has been instrumental in driving the company's growth and innovation since assuming the role of CEO in 2019. Under his leadership, Insulet has continued to expand its flagship product, the Omnipod insulin management system, which has gained widespread adoption among diabetes patients worldwide. Hollingshead has prioritized the development of new technologies and features to enhance the user experience and improve health outcomes for people living with diabetes. His strategic vision has also led to the successful launch of the Omnipod DASH system, which offers a more intuitive and user-friendly interface. Hollingshead's achievements at Insulet have been recognized by the industry, with the company receiving numerous awards and accolades for its innovative products and commitment to improving the lives of diabetes patients. As CEO, he has fostered a culture of collaboration and excellence within the organization, empowering his team to push the boundaries of what is possible in diabetes management. With his proven track record of leadership and dedication to advancing healthcare, James Hollingshead continues to steer Insulet towards a future of growth, innovation, and positive impact on the global diabetes community.